Page 30 - Celularity Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article FLORHAM PARK, N.J. and GAITHERSBURG, Md., May 25, 2021 /PRNewswire/ -- Celularity, Inc. ("Celularity"), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform license. Celularity will obtain non-exclusive rights to use MaxCyte's Flow Electroporation...

TRADING UPDATES: Bank of Cyprus outlook hinges on tourism industry Tue, 25th May 2021 19:40 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Bank of Cyprus Holdings PLC - Strovolos, Cyprus-headquartered financial services firm - Reports total income of EUR136 million in first quarter of 2020, down from EUR145 million a year prior. Swings to pretax profit of EUR19 million from EUR18 million loss. Says the full-year outlook remains uncertain, hinging on the recovery of the tourism industry. "The ...

88 Energy News Headlines. 88E Share News. Financial News Articles for 88 Energy Limited Ord Npv (Di) updated throughout the day.

The Placental Stem Cell Advantage As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy? Last month, Celularity announced that the FDA granted Orphan Drug Designation status to the company’s lead therapeutic candidate, CYNK-001, for the treatment of malignant gliomas. The month prior, the same candidate received Fast Track Designation. These designations mark importa...

Share this article Share this article NEW YORK, May 14, 2021 /PRNewswire/ -- GX Acquisition Corp. ("GX") (NASDAQ: GXGX), a publicly-traded special purpose acquisition company, announced today that its stockholders have voted to approve an amendment to GX's amended and restated certificate of incorporation to extend the date by which GX must effectuate its initial business combination  from May 23, 2021 to July 31, 2021. As previously disclosed, on January 8, 2021, GX entered into a Merger Agreement and Plan of Reorganization (the "Merger Agreement") with Celularity Inc. ("Celularity"), Alph...